Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: An Egyptian pilot study

Ramzy, Iman; Hasaballah, Maha; Marzaban, Raghda; Shaker, Olfat G.; Abdellatif, Zeinab

doi:10.1016/j.clinre.2014.12.008

Cited by 31 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirty-four studies investigating plasma or serum miRNAs in the diagnosis of CRC were included for the final systematic review (Ng et al , 2009; Huang et al , 2010; Pu et al , 2010; Ahmed et al , 2012; Kanaan et al , 2012; Wang and Zhang, 2012; Wang et al , 2012b; Brunet Vega et al , 2013; Giraldez et al , 2013; Hofsli et al , 2013; Kanaan et al , 2013; Liu et al , 2013; Luo et al , 2013; Toiyama et al , 2013; Yu et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Perilli et al , 2014; Xu et al , 2014; Zanutto et al , 2014; Zheng et al , 2014; Basati et al , 2015; Chen et al , 2015; Fang et al , 2015; Ghanbari et al , 2015; Ho et al , 2015; Ramzy et al , 2015; Wang et al , 2015; Li et al , 2015; Li et al , 2016; Sun et al , 2016; Wang et al , 2016; Yu et al , 2016) and of these 19 were included in the meta-analysis (Ng et al , 2009; Huang et al , 2010; Pu et al , 2010; Kanaan et al , 2012; Wang and Zhang, 2012; Wang et al , 2012b; Liu et al , 2013; Toiyama et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Xu et al , 2014; Basati et al , 2015; Chen et al , 2015; Fang et al , 2015; Li et al , 2016; Sun et al , 2016; Wang et al , 2016; Yu et al , 2016). Of these 34 studies, 20 (59%) used plasma (Ng et al , 2009; Huang et al , 2010; Pu et al , 2010; Ahmed et al , 2012; Kanaan et al , 2012; Wang et al , 2012b; Giraldez et al , 2013; Kanaan et al , 2013; Luo et al , 2013; Zhang et al , 2013; Du et al , 2014; Perilli et al , 2014; Xu et al , 2014; …”

Section: Resultsmentioning

confidence: 99%

“…Sixteen of the 34 studies performed miRNA screening studies (Ng et al , 2009; Ahmed et al , 2012; Kanaan et al , 2012; Wang et al , 2012b; Brunet Vega et al , 2013; Giraldez et al , 2013; Hofsli et al , 2013; Kanaan et al , 2013; Luo et al , 2013; Zheng et al , 2014; Xu et al , 2014; Ghanbari et al , 2015; Ho et al , 2015; Wang et al , 2015; Li et al , 2015; Sun et al , 2016) in order to identify dysregulated miRNAs in the plasma or serum of CRC cases compared with healthy controls, whereas the remaining 18 studies identified miRNAs for assessment based on the literature or based on their own prior studies (Huang et al , 2010; Pu et al , 2010; Wang and Zhang, 2012; Liu et al , 2013; Yu et al , 2013; Toiyama et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Perilli et al , 2014; Zanutto et al , 2014; Basati et al , 2015; Chen et al , 2015; Fang et al , 2015; Ramzy et al , 2015; Li et al , 2016; Wang et al , 2016; Yu et al , 2016). A total of 617 miRNAs were differentially expressed between CRC and healthy controls in these screening studies, and of these, 69 miRNAs were found to be significantly dysregulated in validation or subsequent studies.…”

Section: Resultsmentioning

confidence: 99%

“…Thirty-one miRNAs were found to be either upregulated ( n =17, miR-17-3p, miR-18a, miR-19a-3p, miR-20a, miR-21, miR-29a, miR-92, miR-96, miR-106a, miR-182, miR-200c, miR-206, miR-210, miR-221, miR-223-3p, miR-372, miR-378) (Ng et al , 2009; Huang et al , 2010; Pu et al , 2010; Kanaan et al , 2012; Wang and Zhang, 2012; Brunet Vega et al , 2013; Liu et al , 2013; Toiyama et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Perilli et al , 2014; Xu et al , 2014; Zanutto et al , 2014; Zheng et al , 2014; Chen et al , 2015; Yamada et al , 2015; Li et al , 2015; Sun et al , 2016; Wang et al , 2016; Yu et al , 2016) or downregulated ( n =14, miR-24, miR-26a-5p, miR-29b, miR-30b, miR-142-3p, miR-145, miR-194, miR-218, miR-320a, miR-375, miR-422a, miR-423-5p, miR-601, miR-760) (Wang et al , 2012b; Yu et al , 2013; Xu et al , 2014; Zheng et al , 2014; Basati et al , 2015; Fang et al , 2015; Ghanbari et al , 2015; Ho et al , 2015; Ramzy et al , 2015; Li et al , 2015; Li et al , 2016) in CRC cases as compared with controls (Table 2). Six upregulated miRNAs (miR-17-3p, miR-18a, miR-21, miR-29a, miR-92, miR-106a) and two downregulated miRNAs (miR-29b, miR-145) were identified by more than one study (Ng et al , 2009; Huang et al , 2010; Kanaan et al , 2012; Wang and Zhang, 2012; Brunet Vega et al , 2013; Liu et al , 2013; Toiyama et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Zanutto et al , 2014; Zheng et al , 2014; Basati et al , 2015; Chen et al , 2015; Ramzy et al , 2015; Yamada et al , 2015; Li et al , 2015; Li et al , 2016).…”

Section: Resultsmentioning

confidence: 99%

“…Six upregulated miRNAs (miR-17-3p, miR-18a, miR-21, miR-29a, miR-92, miR-106a) and two downregulated miRNAs (miR-29b, miR-145) were identified by more than one study (Ng et al , 2009; Huang et al , 2010; Kanaan et al , 2012; Wang and Zhang, 2012; Brunet Vega et al , 2013; Liu et al , 2013; Toiyama et al , 2013; Zhang et al , 2013; Basati et al , 2014; Du et al , 2014; Zanutto et al , 2014; Zheng et al , 2014; Basati et al , 2015; Chen et al , 2015; Ramzy et al , 2015; Yamada et al , 2015; Li et al , 2015; Li et al , 2016). miR-21 was the most frequently identified dysregulated miRNA (Kanaan et al , 2012; Wang and Zhang, 2012; Liu et al , 2013; Toiyama et al , 2013; Basati et al , 2014; Du et al , 2014; Zanutto et al , 2014; Yamada et al , 2015).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

Background:Colorectal cancer (CRC) is common and associated with significant mortality. Current screening methods for CRC lack patient compliance. microRNAs (miRNAs), identified in body fluids, are negative regulators of gene expression and are dysregulated in many cancers, including CRC. This paper summarises studies identifying blood-based miRNAs dysregulated in CRC compared with healthy controls in an attempt to evaluate their use as a screening tool for the diagnosis of CRC.Methods:A search of electronic databases (PubMed and EMBASE) and grey literature was performed between January 2002 and April 2016. Studies reporting plasma or serum miRNAs in the diagnosis of CRC compared with healthy controls were selected. Patient demographics, type of patient sample (serum or plasma), method of miRNA detection, type of normalisation, and the number of significantly dysregulated miRNAs identified were recorded. Statistical evaluation of dysregulated miRNAs using sensitivity, specificity, and area under the curve (AUC) was performed.Results:Thirty-four studies investigating plasma or serum miRNAs in the diagnosis of CRC were included. A total of 31 miRNAs were found to be either upregulated (n=17) or downregulated (n=14) in CRC cases as compared with controls. Fourteen studies identified panels of ⩾2 dysregulated miRNAs. The highest AUC, 0.943, was identified using a panel of 4 miRNAs with 83.3% sensitivity and 93.1% specificity. Meta-analysis of studies identifying a single dysregulated miRNA in CRC cases compared with controls was performed. Overall sensitivity and specificity of 28 individual miRNAs in the diagnosis of CRC were 76% (95% CI 72%–80%) and 76% (95% CI 72%–80%), respectively, indicating good discriminative ability of miRNAs as biomarkers for CRC. These data did not change with sensitivity analyses.Conclusions:Blood-based miRNAs distinguish patients with CRC from healthy controls with high sensitivity and specificity comparable to other common and invasive currently used screening methods for CRC. In future, miRNAs may be used as a relatively non-invasive blood-based marker for detection of CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Using the described searching strategy above, a total of 297 articles were initially retrieved out of the selected databases. After manually screening the titles, abstracts and keywords and then checking the full texts, 9 articles involving 10 studies for individual miR-29 and 5 articles containing 6 studies for miRNA combination markers based on miR-29 that met the inclusion norm were finally selected for the diagnostic meta-analysis while six publications including eight studies evaluating the survival outcome were identified eligible in the prognostic meta-analysis [27][28][29][30][31][32][33][34][35][36][37][38][39]. Moreover, three studies assessed the roles of miR-29 and miRNA combination markers in the recurrence prediction of CRC and one study evaluated the biomarker role in the metastasis prediction in CRC [40][41][42][43].…”

Section: Study Identification and Characteristics Of Included Studiesmentioning

confidence: 99%

Integrated analyses of microRNA-29 family and the related combination biomarkers demonstrate their widespread influence on risk, recurrence, metastasis and survival outcome in colorectal cancer

et al. 2019

View full text Add to dashboard Cite

Background Emerging evidence has revealed miR-29 family as promising biomarkers for colorectal cancer (CRC), but their biomarker potential and molecular mechanisms remain poorly understood. Methods We performed a comprehensive meta-analysis to evaluate the biomarker performance of individual miR-29 and the related miRNA combination biomarkers. Meanwhile, we conducted an integrative bioinformatics analysis to unfold the underlying biological function of miR-29 and their relationship with CRC. Results Using miR-29 expression to diagnose CRC produced 0.82 area under the curve, 70% sensitivity and 81% specificity while the combination biomarkers based on miR-29 enhanced the diagnostic power with an AUC of 0.86, a sensitivity of 78% and a specificity of 91%. For the prognosis evaluation, patients with higher expression of miR-29 had better survival outcome (pooled HR 0.78; 95% CI 0.56–1.07). In addition, miR-29 has also been identified as potential biomarker for predicting recurrence and metastasis in CRC. Then the genes regulated by the miR-29 family were retrieved and found closely associated with the molecular pathogenesis of CRC according to the gene ontology and pathway analysis. Furthermore, hub nodes and significant modules were identified from the protein–protein interaction network constructed with miR-29 family targets, which were also confirmed highly involved in the establishment and development of CRC. Conclusions Current evidences suggest miR-29 family may become promising biomarkers for risk, recurrence, metastasis and survival outcome of CRC. Meanwhile our data highlight the potential clinical use of miRNA combination biomarkers. Nevertheless, further prospective studies are warranted before the application of the useful biomarkers in the clinical.

show abstract

MicroRNAs expression profiling in Egyptian colorectal cancer patients

et al. 2019

View full text Add to dashboard Cite

Egypt has increased incidence and high rate of early onset colorectal cancer (CRC). This study aimed to profile the expression levels of 84 circulating microRNAs (miRNAs) in Egyptian CRC patients and to evaluate the diagnostic accuracy of some selected miRNAs as diagnostic biomarkers for CRC patients. A total of 129 subjects (84 CRC patients and 45 healthy controls) were enrolled in two independent sample sets: the screening set (39 subjects) and the validation set (90 subjects). The expression profiles of 84 miRNAs were studied by miRNA PCR array in the screening set. Then four miRNAs (let‐7c, 21, 26a, 146a) were selected to be studied by quantitative real‐time PCR in the validation set. The PCR array results revealed significant up regulation of 20 miRNAs and downregulation of two miRNAs in CRC patients compared to the healthy subjects. Moreover, the expression levels of the four selected miRNAs were significantly higher in CRC serum samples than controls. The ROC analysis revealed that miRNAs (let‐7c, 21, 26a and 146a) can effectively discriminate between CRC patients and the controls. The combination of the four miRNAs showed AUC of 0.950 (95% CI [0.898–1.002], p = .001). However, the combination of miR‐21 and miR‐26a showed the best diagnostic accuracy with AUC of 0.953 (95% CI [0.908–0.999], p = .001). The current data suggest that miRNAs (let‐7c, 21, 26a, 146a) could play an important role in CRC development and they can be used as diagnostic biomarkers for CRC.

show abstract

Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: An Egyptian pilot study

Cited by 31 publications

References 38 publications

Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis

Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis

Integrated analyses of microRNA-29 family and the related combination biomarkers demonstrate their widespread influence on risk, recurrence, metastasis and survival outcome in colorectal cancer

MicroRNAs expression profiling in Egyptian colorectal cancer patients

Contact Info

Product

Resources

About